627 related articles for article (PubMed ID: 28284319)
21. Omalizumab in the treatment of allergic bronchopulmonary aspergillosis: One center's experience with 14 cases.
Aydın Ö; Sözener ZÇ; Soyyiğit Ş; Kendirlinan R; Gençtürk Z; Mısırlıgil Z; Mungan D; Sin BA; Demirel YS; Çelik GE; Bavbek S
Allergy Asthma Proc; 2015; 36(6):493-500. PubMed ID: 26534756
[TBL] [Abstract][Full Text] [Related]
22. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.
Pilon D; Kavati A; Ortiz B; Paknis B; Vegesna A; Schiffman B; Zhdanava M; Lefebvre P; Stone B
Allergy Asthma Proc; 2018 Mar; 39(2):127-135. PubMed ID: 29208079
[TBL] [Abstract][Full Text] [Related]
23. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
Korn S; Thielen A; Seyfried S; Taube C; Kornmann O; Buhl R
Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
[TBL] [Abstract][Full Text] [Related]
24. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
25. "Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.
Alhossan A; Lee CS; MacDonald K; Abraham I
J Allergy Clin Immunol Pract; 2017; 5(5):1362-1370.e2. PubMed ID: 28351783
[TBL] [Abstract][Full Text] [Related]
26. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
27. Small, Prospective, Observational, Pilot Study in Patients with Severe Asthma after Discontinuation of Omalizumab Treatment.
Krčmová I; Novosad J; Malá E; Krejsek J
Clin Ther; 2018 Nov; 40(11):1942-1953. PubMed ID: 30391022
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis.
Voskamp AL; Gillman A; Symons K; Sandrini A; Rolland JM; O'Hehir RE; Douglass JA
J Allergy Clin Immunol Pract; 2015; 3(2):192-9. PubMed ID: 25640470
[TBL] [Abstract][Full Text] [Related]
29. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
Rottem M
J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of omalizumab (Xolair®) in patients with moderate to severe predominately chronic oral steroid dependent asthma in Taiwan: a retrospective, population-based database cohort study.
Chen HC; Huang CD; Chang E; Kuo HP
BMC Pulm Med; 2016 Jan; 16():3. PubMed ID: 26747278
[TBL] [Abstract][Full Text] [Related]
31. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
[TBL] [Abstract][Full Text] [Related]
32. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.
Hew M; Gillman A; Sutherland M; Wark P; Bowden J; Guo M; Reddel HK; Jenkins C; Marks GB; Thien F; Rimmer J; Katsoulotos GP; Cook M; Yang I; Katelaris C; Bowler S; Langton D; Wright C; Bint M; Yozghatlian V; Burgess S; Sivakumaran P; Yan KY; Kritikos V; Peters M; Baraket M; Aminazad A; Robinson P; Jaffe A; Powell H; Upham JW; McDonald VM; Gibson PG
Clin Exp Allergy; 2016 Nov; 46(11):1407-1415. PubMed ID: 27377155
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
34. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
35. Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.
Liu MC; Chipps B; Munoz X; Devouassoux G; Bergna M; Smith SG; Price RG; Galkin DV; Azmi J; Mouneimne D; Albers FC; Chapman KR
Respir Res; 2021 May; 22(1):144. PubMed ID: 33971856
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
37. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
Chipps BE; Figliomeni M; Spector S
Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
[TBL] [Abstract][Full Text] [Related]
38. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
Busse WW; Massanari M; Kianifard F; Geba GP
Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
[TBL] [Abstract][Full Text] [Related]
39. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
40. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
